c-fes基因在白血病细胞中的表达及其临床意义

Expression of c-fes Gene in Leukemia Cells and Its Clinical Significance

本研究观察了c-fes基因在急、慢性白血病患者骨髓细胞中的表达情况,并探讨其临床意义。采用实时定量逆转录-聚合酶链反应(RQ-PCR)方法,分别检测121例急、慢性白血病患者骨髓和20例正常人外周血单个核细胞中c-fes mRNA的表达水平。结果表明,急性髓系白血病(AML)患者组c-fes基因相对表达量(48.017±57.170)×10-3高于正常对照组(0.152±0.398)×10-3(p<0.0001);急性淋巴细胞白血病(ALL)患者组c-fes基因相对表达量(0.047±0.068)×10-3与正常对照组相比无差异(p=0.178);慢性髓系白血病(CML)患者组c-fes基因相对表达量(21.605±24.818)×10-3高于正常对照组(p<0.0001)。CML慢性期阳性率(80%)高于加速期(66.7%)和急变期(28.6%),AML患者中c-fes基因阳性率最高的亚型是M2和M3,分别为80.77%、92.86%。初治AML(非M3)患者中,c-fes基因表达阳性患者的CR率(81.08%)高于不表达患者(40.00%)。结论:c-fes基因主要在髓系表达,在淋系中无表达或低表达;c-fes基因在髓系分化方面具有一定的作用,c-fes基因表达高的除M3外的AML患者CR率高,预后好。

This study was purposed to investigate the expression of c-fes gene in leukemia patients and its clinical significance. The expression of c-fes mRNA in bone marrow cells from 121 cases of acute and chronic leukemia patients, and the expression of c-fes mRNA in peripheral blood mononuclear cells of 20 normal persons were detected by real time-quatitative reverse transcription polymerase chain reaction（ RQ-PCR）. The results showed that the level of c-fes mRNA in AML patients was higher than that in normal controls [ （48. 017 ±57. 170） × 10-3 vs （0. 152 ±0. 398） × 10-3 （p 〈0. 0001 ） ; but there was no significant differences of level of c-fes mRNA between samples of ALL and normal controls（0.047 ±0. 068） × 10-3 vs（0. 152 ± 0. 398） × 10-3 （p 〉 0.05） ; the level of c-fes mRNA in CML patients was higher than that in normal persons （21. 605±24. 818 ） × 10-3 vs （0. 152 ± 0. 398 ） × 10-3 （p 〈 0. 0001 ）. The positive expression rate of c-fes gene in CML-CP patients （ 80% ） was higher than that in CML-AP patients （ 66. 7% ） and CML-BP （ 28, 6% ） patients. In AML patients, c-fes gene was expressed higher in M2 （ 80, 77% ） and M3 （92. 86% ） patients. The remission rate of AML（ except M3 ） patients who had expression of c-fes gene was 81.08%, which was higher than that of patients with no expression of c-fes gene （40.00%） . It is concluded that c-fes gene expression was found in myeloid leukemias, whereas low or no expression in lymphocytic leukemias. The differentiation of myelocytic cells may be related to c-fes gene. All AML （ except M3 ） patients with high level of c-fes mRNA may get good prognosis.